» Articles » PMID: 17166244

Microparticle-associated Tissue Factor Activity: a Link Between Cancer and Thrombosis?

Overview
Publisher Elsevier
Specialty Hematology
Date 2006 Dec 15
PMID 17166244
Citations 212
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer, in particular mucinous adenocarcinoma, is associated with venous thromboembolism (VTE). Tissue factor (TF), initiator of coagulation, plays a central role in the paradigm that clotting and tumor growth form a vicious circle, in which hypercoagulability facilitates the aggressive biology of cancer and vice versa. Expression of TF in tumors is associated with poor differentiation and poor prognosis.

Patient/methods: We investigated the association between clinically manifest VTE and procoagulant properties of circulating microparticles (MP) isolated from blood of unselected pancreatic and breast adenocarcinoma patients' consecutive subjects, who presented with ultrasound or CT-scan confirmed VTE, and healthy subjects.

Results: Patients with disseminated breast and pancreatic cancer had significantly increased levels of MP-associated TF activity compared with healthy controls, subjects with idiopathic acute VTE and non-metastatic cancer patients. Patients with both high MP-associated TF-activity and MP-associated epithelial mucin (MUC1) had a lower survival rate at 3-9 months follow-up than those with low TF-activity and no MUC1 expression: the likelihood of survival was 0.42 (95% CI: 0.19- 0.94) for an individual with these two predictor variables present, after adjustment for other factors (age cohort, type of cancer, VTE) in the Cox proportional hazards model.

Conclusions: Our results suggest an important role for MP-associated TF and MUC1 in the pathogenesis of thrombosis in disseminated mucinous adenocarcinoma patients. Future studies should reveal the mechanism underlying the observed associations.

Citing Articles

Comparison of the procoagulant activity between extracellular vesicles obtained from cellular monolayers and spheroids.

Rondon A, Featherby S, Gomes T, Laghmani E, Ettelaie C, Versteeg H J Thromb Thrombolysis. 2025; .

PMID: 40042717 DOI: 10.1007/s11239-025-03076-4.


Circulating, Extracellular Vesicle-Associated Tissue Factor in Cancer Patients with and without Venous Thromboembolism.

Lami V, Nieri D, Pagnini M, Gattini M, Donati C, De Santis M Biomolecules. 2025; 15(1.

PMID: 39858477 PMC: 11762650. DOI: 10.3390/biom15010083.


Successful Management of Disseminated Intravascular Coagulation in Metastatic Castrate-Resistant Prostate Cancer With Lutetium-177: A Case Report and Review of the Literature.

Zheng J, Ibezue C, Nguyen N, Cai Q, Qin Q, Wang J Cureus. 2025; 16(12):e75107.

PMID: 39764338 PMC: 11701786. DOI: 10.7759/cureus.75107.


Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.

Li K, Guo B, Gu J, Ta N, Gu J, Yu H Mater Today Bio. 2025; 30:101375.

PMID: 39759851 PMC: 11699619. DOI: 10.1016/j.mtbio.2024.101375.


Machine learning-based model for CD4 conventional T cell genes to predict survival and immune responses in colorectal cancer.

Wang Z, Sun Z, Lv H, Wu W, Li H, Jiang T Sci Rep. 2024; 14(1):24426.

PMID: 39424871 PMC: 11489786. DOI: 10.1038/s41598-024-75270-y.